Tafalgie Therapeutics, founded in Marseille in 2020 as a spin-off of the CNRS and the Institut de Biologie du Développement de Marseille, develops painkillers derived from TAFA4, a protein the body secretes that, according to more than 15 years of research by co-founder Aziz Moqrich, reduces pain signals after tissue damage. It was selected in the EIC Accelerator's June 2023 cut-off with blended finance and received an EU grant of €2.50 million for a €17.39 million project running from March 2024 to November 2026, according to CORDIS. The grant covers just 14% of the project's cost.
The first report, to June 2025, says Tafalgie "entered the clinical phase in May 2025" with its first lead compound, filed four new patents and built "a team of 26 employees", and that a Phase 2a protocol was being finalised "with the aim of starting trials in H1 2026", according to the CORDIS reporting page. In July 2025 the company reported that the first healthy volunteers in TAFAFIRST, its trial of the peptide TT5 in Australia, showed "an excellent safety profile" with no opioid-like side effects such as sedation or respiratory depression, according to Tafalgie Therapeutics. The Fondation pour la Recherche Médicale reports that TT5 was tested in 64 healthy volunteers without adverse effects and that a test in about 100 surgical patients is under way, with first results "attendus fin 2026", according to the FRM.
Company file
- Legal entity
- Tafalgie Therapeutics, SIREN 891 031 148, Marseille
- Scientific co-founder
- Aziz Moqrich, CNRS Innovation Medal 2025
- Lead drug
- TT5, TAFA4-derived peptide, intravenous
- Trial
- TAFAFIRST, Australia, CMAX and Royal Adelaide Hospital
- Investors
- Founders, business angels, family offices
- Staff
- 26, per company
- EIC funding
- Blended finance
Where Tafalgie Stands Now
In September 2025 Tafalgie raised €12 million in a Series A from family offices and existing investors, bringing equity raised since 2020 to €30 million, to fund TT5 "jusqu'à la finalisation de sa Phase 2A", according to its press release. It said it would soon complement the round with a further financing. It has been financed entirely by founders, business angels and family offices rather than venture funds, which it called unusual for a biotech. The TAFAFIRST trial registry entry lists it as recruiting, with 94 participants planned and completion estimated for November 2026, according to ClinicalTrials.gov.
"Tafalgie Therapeutics entered the clinical phase in May 2025 with its first lead, a first-in-class compound selected from its large portfolio of patented TAFA4 peptide derivatives."
Tafalgie Therapeutics, first periodic report to the EICThe Technology: A Pain Brake the Body Already Makes
Opioids remain the strongest painkillers but cause addiction and tolerance; the report cites more than 727,000 opioid deaths in the United States between 1999 and 2022. TAFA4 works differently: it acts both on peripheral nerve fibres and in the spinal cord to damp pain signals, and the company says it could modify the course of pain rather than only mask it. TT5 is a short active piece of the protein given by intravenous infusion; the company is also developing forms for injection under the skin and by mouth.
What the EIC Award Promises, and What the Record Shows
The project aims to take TAFA4 derivatives into the clinic and prove their concept in patients. Tafalgie has reached the clinic and reports good safety in volunteers. The efficacy test in surgical patients is the step that matters, and its results are due around the time the EIC project ends in November 2026. The report's target of starting a separate Phase 2a trial in the first half of 2026 has not been confirmed publicly.
- First human trialDeliveredMay 2025, Australia.
- Safety in volunteersDelivered64 volunteers, per FRM.
- Efficacy in patientsPendingResults end 2026.
- Financing for Phase 2aDelivered€12M Series A.
The Money
The report says the company had "secured €37 million in funding to date, including €30 million in capital". Its accounts are not in the public ratios dataset. Whether the EIC Fund invested under the blended award has not been announced; the Series A release names only family offices and existing investors.
What Cannot Be Checked
Questions for the EIC
Whether the EIC Fund invested, whether the separate Phase 2a trial has started, and whether TT5 reduces pain in patients are not public yet.
Why Europe Should Care
Chronic pain affects 1.5 billion people worldwide, the report says, citing the WHO, and Europe's opioid use is rising. A painkiller without addiction risk would be one of the most valuable drugs in medicine. The EIC's share of this project is small, but it backed an early bet that has reached people.
What the award promises
A first-in-class non-opioid painkiller taken into the clinic and tested in patients.
What the record shows
A drug in human trials with good early safety and patient results due by the end of 2026.
The Verdict
On track, not yet proven
Tafalgie has done what it said on the timeline it set. Whether TT5 relieves pain is the question the next months will answer.
Tafalgie Therapeutics and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
